Patents by Inventor Yuling Li
Yuling Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10921673Abstract: An electrochromic device includes a first flexible substrate, a first transparent electrode disposed on the first flexible substrate, an electrochromic layer disposed on the first transparent electrode, and a solid electrolyte layer disposed on the electrochromic layer. The solid electrolyte layer contains less than 20 wt % of neutral small organic molecules having a molecular weight of 3000 or less. The electrochromic device further includes an ion storage layer disposed on the solid electrolyte layer, a second transparent electrode disposed on the ion storage layer, and a second flexible substrate disposed on the second transparent electrode.Type: GrantFiled: July 29, 2020Date of Patent: February 16, 2021Assignee: AMBILIGHT INC.Inventors: Jiazhi He, Hong Wang, Chao Wang, Yuling Li, Liyan You, Yu Zhou
-
Publication number: 20210041757Abstract: An electrochromic apparatus includes a first glass, a first adhesive layer disposed on the first glass, a second glass, a second adhesive layer disposed on the second glass, a solid-state electrochromic device (ECD) interposed between the first adhesive layer and the second adhesive layer, and a sealant disposed at edges of the first glass and the second glass to seal the ECD. The first adhesive layer and the second adhesive layer are disposed between the first glass and the second glass. The first adhesive layer and the second adhesive layer are optically transparent. Edges of the adhesive layers are flush with or beyond edges of the ECD. The sealant is adhesive and waterproof.Type: ApplicationFiled: October 21, 2020Publication date: February 11, 2021Inventors: Jiazhi HE, Hong WANG, Chao WANG, Yuling LI, Liyan YOU, Yu ZHOU
-
Publication number: 20200363692Abstract: An electrochromic device includes a first flexible substrate, a first transparent electrode disposed on the first flexible substrate, an electrochromic layer disposed on the first transparent electrode, and a solid electrolyte layer disposed on the electrochromic layer. The solid electrolyte layer contains less than 20 wt % of neutral small organic molecules having a molecular weight of 3000 or less. The electrochromic device further includes an ion storage layer disposed on the solid electrolyte layer, a second transparent electrode disposed on the ion storage layer, and a second flexible substrate disposed on the second transparent electrode.Type: ApplicationFiled: July 29, 2020Publication date: November 19, 2020Inventors: Jiazhi HE, Hong WANG, Chao WANG, Yuling LI, Liyan YOU, Yu ZHOU
-
Publication number: 20140358220Abstract: Adipose tissue has proven to serve as an abundant, accessible, and rich source of endothelial or vascular endothelial cells suitable for tissue engineering. We describe a detailed method for the isolation and purification of endothelial cells using purified enzymes and antibody-based selection. The cells can be obtained from liposuction procedures and used in vascular grafts.Type: ApplicationFiled: August 18, 2014Publication date: December 4, 2014Inventors: Laura E. NIKLASON, Yuling LI
-
Publication number: 20140356323Abstract: The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.Type: ApplicationFiled: August 18, 2014Publication date: December 4, 2014Inventors: Laura E. Niklason, Yuling Li, Juliana Blum, Shannon L.M. Dahl, Geoffrey Erickson, Frank Zeigler
-
Publication number: 20120230950Abstract: The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.Type: ApplicationFiled: May 21, 2012Publication date: September 13, 2012Applicant: Humacyte, Inc.Inventors: Laura Niklason, Yuling Li, Juliana Blum, Shannon Dahl, Geoffrey Erickson, Frank Zeigler
-
Patent number: 8198245Abstract: The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.Type: GrantFiled: July 24, 2008Date of Patent: June 12, 2012Assignee: Humacyte, Inc.Inventors: Laura Niklason, Yuling Li, Juliana Blum, Shannon Dahl, Geoffrey Erickson, Frank Zeigler
-
Publication number: 20110020271Abstract: The present invention provides compositions comprising isolated elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.Type: ApplicationFiled: May 20, 2010Publication date: January 27, 2011Applicant: Humacyte, Inc.Inventors: Laura E. Niklason, Yuling Li, Heather Prichard, Shannon Dahl, Juliana Blum
-
Publication number: 20090319033Abstract: Adipose tissue has proven to serve as an abundant, accessible, and rich source of endothelial or vascular endothelial cells suitable for tissue engineering. We describe a detailed method for the isolation and purification of endothelial cells using purified enzymes and antibody-based selection. The cells can be obtained from liposuction procedures and used in vascular grafts.Type: ApplicationFiled: March 7, 2007Publication date: December 24, 2009Applicant: HumacyteInventors: Laura E Niklason, Yuling Li
-
Publication number: 20090028817Abstract: The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.Type: ApplicationFiled: July 24, 2008Publication date: January 29, 2009Inventors: Laura Niklason, Yuling Li, Juliana Blum, Shannon Dahl, Geoffrey Erickson, Frank Zeigler
-
Publication number: 20070238644Abstract: Human chemokine polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed.Type: ApplicationFiled: November 21, 2006Publication date: October 11, 2007Applicant: Human Genome Sciences, Inc.Inventors: Haodong Li, Mark Adams, Solange Lima, Ralph Alderson, Yuling Li, David Parmelee, John White, Edward Appelbaum
-
Publication number: 20070026500Abstract: The invention relates to a Neutrokine-alpha protein in crystalline form, a method of preparing a Neutrokine-alpha protein in crystalline form, and methods of using a Neutrokine-alpha protein in crystalline form. In particular, the three-dimensional structure of a Neutrokine-alpha protein in crystalline form is used to design molecules that have biological activity. The methods are useful for designing compounds that bind to a Neutrokine-alpha protein, inhibit a Neutrokine-alpha protein, mimic a Neutrokine-alpha protein, and/or enhance the activity of a Neutrokine-alpha protein. The three-dimensional structure of a Neutrokine-alpha protein, as provided herein, is also used to determine the three-dimensional of other Neutrokine-alpha proteins and homologues thereof.Type: ApplicationFiled: May 6, 2004Publication date: February 1, 2007Inventors: Yuling Li, Deena Oren, Edward Arnold, Yulia Volovik
-
Publication number: 20070015278Abstract: The invention relates to methods of isolating differentiable fetal-derived cells from various tissues of the placenta. Specifically, some of the methods of the present invention relate to isolating differentiable amnion-derived cells, while other methods of the present invention relate to isolating differentiable chorion-derived cells. The present invention also relates to methods of inducing these isolated differentiable amnion-derived and differentiable chorion-derived cells to at least partially differentiate. The present invention also relates to methods of treating insulin deficiencies in a subject by administering these differentiable amnion-derived cells and/or differentiable chorion-derived cells to subjects in need thereof.Type: ApplicationFiled: April 13, 2006Publication date: January 18, 2007Inventors: Yuling Li, JoAnne Garvin, Cynthia Pittman, Friedrich Hahn, Rulling Xu
-
Patent number: 7138498Abstract: Human chemokine polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed.Type: GrantFiled: August 25, 2003Date of Patent: November 21, 2006Assignee: Human Genome Sciences, Inc.Inventors: Haodong Li, Mark D. Adams, Solange H. Gentz, Ralph Alderson, Yuling Li, David Parmelee, John R. White, Edward R. Appelbaum
-
Patent number: 6936688Abstract: Human chemokine Beta-10 polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed.Type: GrantFiled: April 19, 2002Date of Patent: August 30, 2005Assignees: Human Genome Sciences, Inc., SmithKline Beecham Corp.Inventors: Henrik S. Olsen, Haodong Li, Mark D. Adams, Solange H. L. Gentz, Ralph Alderson, Yuling Li, David Parmelee, John R. White, Edward R. Appelbaum
-
Publication number: 20040037805Abstract: Human chemokine polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed.Type: ApplicationFiled: August 25, 2003Publication date: February 26, 2004Applicant: Human Genome Sciences, Inc.Inventors: Haodong Li, Mark D. Adams, Solange H. Gentz, Ralph Alderson, Yuling Li, David Parmelee, John R. White, Edward R. Appelbaum
-
Publication number: 20040024186Abstract: The present invention relates to processes for the purification of proteins. More specifically, methods for solubilizing and purifying proteins expressed in an insoluble form using low concentrations of chaotropic agents, such as guanidine salts, are provided. Also provided are methods for refolding proteins solubilized according to the present invention.Type: ApplicationFiled: July 31, 2003Publication date: February 5, 2004Applicant: Human Genome Sciences, Inc.Inventors: Yuling Li, Mark Oelkuct, Reiner L. Gentz
-
Patent number: 6673344Abstract: Human chemokine polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed.Type: GrantFiled: November 22, 2000Date of Patent: January 6, 2004Assignee: Human Genome Sciences, Inc.Inventors: Haodong Li, Mark Adams, Solange Hanschke Lima, Ralph Alderson, Yuling Li, David Parmelee, John White, Edward Appelbaum
-
Patent number: 6632425Abstract: The present invention relates to processes for the purification of proteins. More specifically, methods for solubilizing and purifying proteins expressed in an insoluble form using low concentrations of chaotropic agents, such as guanidine salts, are provided. Also provided are methods for refolding proteins solubilized according to the present invention.Type: GrantFiled: December 18, 1998Date of Patent: October 14, 2003Assignee: Human Genome Sciences, Inc.Inventors: Yuling Li, Mark Oelkuct, Reiner L. Gentz
-
Publication number: 20030171319Abstract: Human Chemokine Beta-10 polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed.Type: ApplicationFiled: October 3, 2002Publication date: September 11, 2003Inventors: Henrik S. Olsen, Haodong Li, Mark D. Adams, Solange H.L. Gentz, Ralph Alderson, Yuling Li, David Parmelee, John R. White, Edward R. Appelbaum, Theodora Salcedo